Dermatitis News

Dermatologist Raj Chovatiya, MD, PhD, MSCI, recently spoke to Healio about his new findings in seborrheic dermatitis and how to best treat diverse patient groups with this condition.

Topical tapinarof cream showed significant improvement of moderate to severe atopic dermatitis while being well tolerated by adults and children down to age 2 years, according to two phase 3 clinical trials.

Due to a small increase in eczematous dermatitis, older adults taking antihypertensive drugs should be monitored and this possibility considered when assessing for eczema, according to a study.

Johnson & Johnson will pay $850 million to acquire the biotechnology company Proteologix Inc., the company announced in a press release.

Arcutis Biotherapeutics reported Zoryve net sales of $21.6 million in the first quarter of 2024, the company announced in a press release.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company announced in a press release.

Technoderma Medicines has dosed its first patients in its phase 2a clinical trial of topical TDM-180935 ointment for the treatment of atopic dermatitis, the company announced in a press release.

Eli Lilly and Company announced a net revenue increase of 26% in the first quarter of 2024 and the resubmission of its biologic license application for lebrikizumab for the treatment of atopic dermatitis, according to a press release.

SelectION announced positive results from its first-in-human phase 1b trial of its lead compound, a selectively-optimized peptide, for the treatment of patients with atopic dermatitis, according to a company press release.